Jefferies Sees a 3-6 Month Delay for Arena's (ARNA) Lorcaserin But Reiterates Buy Rating
Get Alerts ARNA Hot Sheet
Price: $99.98 --0%
Rating Summary:
10 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 10
Rating Summary:
10 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 10
Join SI Premium – FREE
Jefferies reiterated its Buy rating and $9 price target on Arena Pharma (NASDAQ: ARNA) although it expects a delay for lorcaserin approval.
The firm comments, "Following Friday's conference call, we now expect a slight delay of 3-6 months to lorcaserin approval to finalize a REMS program and/or post-marketing commitments. We are adjusting our model for an early 2013 launch, as well as a likely tax benefit from manufacturing lorcaserin in Switzerland. We remain bullish on likely FDA approval and eventual blockbuster combination sales."
For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.
Shares of Arena Pharma closed at $6.36 yesterday.
The firm comments, "Following Friday's conference call, we now expect a slight delay of 3-6 months to lorcaserin approval to finalize a REMS program and/or post-marketing commitments. We are adjusting our model for an early 2013 launch, as well as a likely tax benefit from manufacturing lorcaserin in Switzerland. We remain bullish on likely FDA approval and eventual blockbuster combination sales."
For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.
Shares of Arena Pharma closed at $6.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY7,800 at Jefferies, 'emerged stronger since the last earnings season'
- Reckitt Benckiser (RKT:LN) (RBGLY) PT Raised to GBP41 at Jefferies
- Portillo's, Inc (PTLO) PT Lowered to $21 at Jefferies, 'an attractive opportunity for investors seeking quality, early-stage growth'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!